Zestoretic: Comprehensive Blood Pressure Control in a Single Tablet
| Product dosage: 17.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.47 | $44.18 (0%) | 🛒 Add to cart |
| 60 | $1.17 | $88.36 $70.28 (20%) | 🛒 Add to cart |
| 90 | $1.07 | $132.54 $96.39 (27%) | 🛒 Add to cart |
| 120 | $1.01 | $176.72 $121.49 (31%) | 🛒 Add to cart |
| 180 | $0.96 | $265.07 $172.70 (35%) | 🛒 Add to cart |
| 270 | $0.93 | $397.61 $250.01 (37%) | 🛒 Add to cart |
| 360 | $0.91
Best per pill | $530.15 $327.32 (38%) | 🛒 Add to cart |
Synonyms | |||
Zestoretic combines two proven antihypertensive agents, lisinopril and hydrochlorothiazide, into a single, convenient tablet for the management of hypertension. This fixed-dose combination therapy is indicated for patients whose blood pressure is not adequately controlled on monotherapy or as initial treatment in patients likely to need multiple drugs to achieve their blood pressure goals. By leveraging complementary mechanisms of action, Zestoretic provides synergistic effects on blood pressure reduction while simplifying the treatment regimen, potentially improving long-term adherence and clinical outcomes in hypertensive patients.
Features
- Contains lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, and hydrochlorothiazide, a thiazide diuretic
- Available in multiple strength combinations: 10/12.5 mg, 20/12.5 mg, and 20/25 mg (lisinopril/hydrochlorothiazide)
- Once-daily oral administration
- White, oval-shaped, film-coated tablets with distinctive imprints for strength identification
- Manufactured under strict pharmaceutical quality control standards
- Stable at room temperature with proper storage conditions
Benefits
- Provides dual-mechanism blood pressure control through RAAS inhibition and sodium/water excretion
- Offers simplified dosing regimen compared to multiple separate medications
- Demonstrates proven efficacy in reducing both systolic and diastolic blood pressure
- May reduce the risk of cardiovascular events associated with uncontrolled hypertension
- Potentially decreases pill burden, improving medication adherence
- Cost-effective compared to purchasing individual components separately
Common use
Zestoretic is primarily prescribed for the treatment of hypertension in patients for whom combination therapy is appropriate. It is commonly used as second-line therapy when monotherapy with either an ACE inhibitor or thiazide diuretic provides insufficient blood pressure control. The medication may also be initiated as first-line treatment in patients with stage 2 hypertension or those with compelling indications for both components. Clinical studies have demonstrated its effectiveness across diverse patient populations, including those with comorbid conditions such as diabetes mellitus (under careful supervision) and heart failure.
Dosage and direction
The dosage of Zestoretic should be individualized based on the patient’s blood pressure response and prior antihypertensive therapy. The usual recommended starting dose is one Zestoretic 10/12.5 tablet once daily. For patients currently receiving lisinopril and hydrochlorothiazide as separate tablets, Zestoretic may be substituted for the individual components. Dosage may be titrated upward after 2-3 weeks of therapy, not to exceed lisinopril 80 mg or hydrochlorothiazide 50 mg daily. The tablets should be taken orally, with or without food, at approximately the same time each day. Dose adjustment is recommended in patients with renal impairment, and the combination is not recommended when creatinine clearance is ≤30 mL/min.
Precautions
Patients should be monitored for hypotension, especially after the initial dose and during dose titration. Renal function and serum electrolytes should be assessed before initiating therapy and periodically during treatment. Caution is advised in patients with impaired renal function, hepatic disease, or pre-existing electrolyte imbalances. Patients should be advised to avoid dehydration and excessive perspiration, which may precipitate hypotension. Angioedema has been reported with ACE inhibitors and may occur at any time during treatment. Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk. Use with caution in patients with collagen vascular disease or those receiving immunosuppressive therapy.
Contraindications
Zestoretic is contraindicated in patients with known hypersensitivity to any component of this product or other sulfonamide-derived drugs. It is contraindicated in patients with a history of angioedema related to previous ACE inhibitor treatment. The combination is contraindicated in patients with anuria and in those who are hypersensitive to other ACE inhibitors. Do not co-administer with aliskiren in patients with diabetes. Contraindicated during the second and third trimesters of pregnancy due to potential fetal harm. Not recommended for use in patients with severe renal impairment (creatinine clearance ≤30 mL/min).
Possible side effect
Common adverse reactions (≥1%) include dizziness, headache, fatigue, cough, orthostatic effects, and gastrointestinal disturbances such as nausea and diarrhea. Less frequent side effects may include hyperkalemia or hypokalemia (depending on patient factors), hyponatremia, hypomagnesemia, hypercalcemia, hyperuricemia, and elevated blood urea nitrogen and serum creatinine. Rare but serious adverse effects include angioedema, pancreatitis, hepatic failure, photosensitivity reactions, and blood dyscrasias. Some patients may experience decreased renal function, particularly those with renal artery stenosis.
Drug interaction
Zestoretic may interact with several medication classes. Concomitant use with other antihypertensive agents may result in additive hypotensive effects. NSAIDs may reduce the antihypertensive efficacy and increase the risk of renal impairment. Potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may increase the risk of hyperkalemia. Lithium levels may increase with concomitant thiazide use. The hypoglycemic effect of insulin and oral antidiabetic agents may be enhanced. Colestipol and cholestyramine may reduce the absorption of hydrochlorothiazide. Alcohol, barbiturates, or narcotics may potentiate orthostatic hypotension.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed dose. Consistent daily administration is important for maintaining stable blood pressure control. Patients should be educated about the importance of adherence and provided with strategies to help remember their medication, such as using pill organizers or associating dosing with daily routines.
Overdose
Symptoms of overdose may include severe hypotension, electrolyte disturbances, dehydration, and renal impairment. Bradycardia, tachycardia, and circulatory shock may occur. Lisinopril overdose may manifest as hypotension, while hydrochlorothiazide overdose may cause excessive diuresis with electrolyte depletion. Management involves supportive care, including volume expansion with normal saline for hypotension. Gastric lavage may be considered if ingestion was recent. Hemodialysis may be effective for removing lisinopril but is less effective for hydrochlorothiazide removal. Serum electrolytes and renal function should be monitored closely, and appropriate corrective measures implemented based on clinical findings.
Storage
Store at controlled room temperature, 20°-25°C (68°-77°F), with excursions permitted between 15°-30°C (59°-86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly discard any unused medication that is no longer needed or has expired. Do not store in bathroom areas where moisture levels may fluctuate. Tablets should be protected from excessive heat and humidity to maintain stability and efficacy.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions should be made by qualified healthcare professionals based on individual patient characteristics and clinical judgment. Patients should not alter their medication regimen without consulting their healthcare provider. The complete prescribing information should be consulted before initiating therapy. While every effort has been made to ensure accuracy, medical knowledge evolves, and new information may become available that could affect the appropriate use of this medication.
Reviews
Clinical trials have demonstrated that Zestoretic effectively reduces blood pressure in a significant majority of hypertensive patients. In comparative studies, the combination therapy showed superior efficacy compared to monotherapy with either component alone. Many clinicians report improved patient adherence and satisfaction with the simplified dosing regimen. Some studies have indicated that fixed-dose combinations like Zestoretic may lead to better long-term blood pressure control compared to free combinations of the same drugs. However, individual responses may vary, and careful monitoring remains essential throughout treatment. Patient reviews often mention appreciation for the convenience of a single tablet while maintaining effective blood pressure control.